Skip to main content

Table 1 Patient Characteristics

From: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Patient Characteristics

N (%)

Age (years), Median (range)

53 (39–76)

Sex

 Male

5 (63)

 Female

3 (37)

Race

 White

7 (88)

 Black

1 (12)

Histology

 Thymoma

7 (88)

 B1

1

 B2

3

 B3

3

 Thymic carcinoma

1 (12)

Stage at presentation

 IVA

1 (12)

 IVB

7 (88)

Previous treatment

 Systemic therapya, Median (range)

3.5 (2–10)

 Thymectomyb

7 (88)

 Chest radiation therapy

7 (88)

  1. a Includes: Cisplatin + Doxorubicin + Cyclophosphamide (PAC), PAC + Prednisone, PAC + Belinostat, Cisplatin + Etoposide, Carboplatin + Etoposide, Carboplatin + Paclitaxel, Gemcitabine + Capecitabine, Cisplatin, Paclitaxel, Gemcitabine, Pemetrexed, Sunitinib, Cixutumumab, Milciclib, Octreotide, Amrubicin, Saracatinib, and Belinostat. bIncludes one case of debulking surgery